References Library

Eli Lilly and Company

Pre-approval Expanded Access of Retatrutide (LY3437943), NCT07629401 (single-patient expanded access; status: Available)

ClinicalTrials.gov record (first posted June 5, 2026; updated August 6, 2026) (2026)

U.S. Food and Drug Administration

Warning Letter to Peptide Partners LLC (MARCS-CMS 735063): unapproved new drugs including 'GLP-3 Reta (Retatrutide)' marketed as research use only

FDA Warning Letter (August 24, 2026) (2026)

Giblin MJ, Haupt A, Engberg S, et al.

Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials

Diabetes, Obesity and Metabolism . 28 : 83-93 (2026)

Eli Lilly and Company

Lilly calls on online platforms, payment companies and regulators to shut down the illegal retatrutide black market

Eli Lilly Press Release (August 12, 2026) (2026)

Eli Lilly and Company

Lilly to present new data on Foundayo, retatrutide and eloraTZP at EASD 2026

Eli Lilly Press Release (September 15, 2026) (2026)

Eli Lilly and Company

Lilly reports second-quarter 2026 financial results, raises full-year guidance and highlights continued growth and pipeline progress

Eli Lilly Press Release (August 5, 2026) (2026)

Eli Lilly and Company

Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial

Eli Lilly Press Release (2026)

Eli Lilly and Company

Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C

Eli Lilly Press Release (July 23, 2026) (2026)

Rosenstock J, Frias JP, Hartman ML, et al.

Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes (TRANSCEND-T2D-1): a randomised, double-blind, placebo-controlled, phase 3 trial

The Lancet (2026)

STAT News

Lilly gave one patient early access to retatrutide. Now other doctors want the same for their patients

STAT News (August 3, 2026) (2026)

Therapeutic Goods Administration (Australia), ABC News

TGA tests counterfeit 'retatrutide' after serious adverse event: product contained no retatrutide but roughly eight times the semaglutide of approved products

TGA Safety Alert / ABC News (September 14, 2026) (2026)

Coskun T, Wu Q, Schloot NC, et al.

Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2 trial

Lancet Diabetes & Endocrinology (2025)

le Roux CW, Steen O, Lucas KJ, et al.

The Effect of Retatrutide on Kidney Parameters in Participants With Type 2 Diabetes Mellitus and/or Obesity

Kidney International Reports (2025)

Eli Lilly and Company

Lilly's retatrutide (LY3437943) showed statistically significant and clinically meaningful results in TRIUMPH-4 Phase 3 trial

Eli Lilly Press Release (2025)

Aronne LJ, Sattar N, Horn DB, et al.

Retatrutide Phase 2 body composition substudy results

Obesity . 32 : 1425-1438 (2024)

Coskun T, Roell WC, Urva S, et al.

Pharmacological profile and mechanisms of the triple GIP/GLP-1/glucagon receptor agonist retatrutide

Diabetes, Obesity and Metabolism . 26 : 816-828 (2024)

Eli Lilly and Company

Lilly provides update on retatrutide phase 3 clinical development program for obesity and type 2 diabetes

Eli Lilly Press Release (2024)

Frias JP, Hsia S, Engberg S, et al.

Retatrutide cardiovascular safety and metabolic parameters in the Phase 2 obesity trial

Diabetes, Obesity and Metabolism (2024)

le Roux CW, Hankosky ER, Wang H, et al.

Retatrutide in chronic kidney disease: design of a phase 2 trial

Kidney International Reports (2024)

Ryan DH, Yockey SR, Garvey WT

GLP-1 receptor agonists and obstructive sleep apnea

Obesity Reviews (2024)

Sanyal AJ, Kaplan LM, Frias JP, et al.

Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial

Nature Medicine . 30 : 2037-2048 (2024)

Wilding JPH, Batterham RL, Davies M, et al.

Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension

Diabetes, Obesity and Metabolism (2024)

Jastreboff AM, Kaplan LM, Frias JP, et al.

Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial

New England Journal of Medicine . 389 : 514-526 (2023)

Rosenstock J, Frias JP, Jastreboff AM, et al.

Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-comparator controlled, parallel-group, phase 2 trial conducted in the USA

The Lancet . 402 : 529-544 (2023)

Rosenstock J, Frias JP, Rodbard HW, et al.

Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-comparator controlled, parallel-group, phase 2 trial conducted in the USA

The Lancet . 402 : 529-544 (2023)

Thomas MK, Nikooienejad A, Bray R, et al.

Dual GIP and GLP-1 receptor agonist tirzepatide improves beta-cell function and insulin sensitivity in type 2 diabetes

Diabetes Care (2023)

Briere DA, Bueno AB, Gunn EJ, et al.

Mechanisms to elevate endogenous GLP-1 beyond injectable GLP-1 analogs and metabolic surgery

Molecular Metabolism (2022)

Coskun T, Urva S, Roell WC, et al.

LY3437943, a novel triple GIP/GLP-1/glucagon receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept

Cell Metabolism . 34 : 1234-1247.e9 (2022)

Coskun T, Urva S, Roell WC, et al.

LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept

Cell Metabolism . 34 : 1234-1247.e9 (2022)

Urva S, Coskun T, Loh MT, et al.

LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial

The Lancet . 400 : 1869-1881 (2022)